Pfizer Decides Not To Challenge AbbVie's Humira Biosimilar Patents

 
• By Brenda Sandburg

Pfizer is the seventh company to enter licensing agreement with AbbVie; it has completed development program for its adalimumab candidate.

Adalimumab monoclonal antibody drug. Anti-inflammatory TNF-alpha inhibitor used in treatment of rheumatoid arthritis, psoriasis, ulcerative colitis, etc. Generic name and stylized antibody.

More from Biosimilars

More from Biosimilars & Generics